RxDoctor Payments Data

Behram Mody, MD

Advanced Heart Failure and Transplant Cardiology · Orange, CANPI 1720346240

Payments from drug & device makers

What this record shows

This record is dominated by grants: $11,250 of the $16,501 with a category attached, or 68.2%. Medtronic accounts for 77.0% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $12,859 and has fallen 91.6% since, to $1,081 in 2025.

$16,501in general payments, 2019–2025

Across 50 payments — averaging $330.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$13K
  • Edwards Lifesciences$2K
  • Abiomed$902
  • E.r. Squibb & Sons, L.L.C.$412
  • Abbott$382
  • Novartis$137
  • plus $421 from 5 others
$175,228in research payments, 2019–2025

Across 46 payments — averaging $3809.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$90K
  • Bayer$85K

What the payments were for

  • Grants$11,25068%
  • Travel & lodging$2,31714%
  • Food & beverage$2,72917%
  • Education$2051%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,501 in reported general payments places this provider in the 60th percentile of 111 advanced heart failure and transplant cardiology providers in California.

See all advanced heart failure and transplant cardiology providers in California

Medicare billing

Part B allowed, 2024
$149,601
Medicare patients
1,533
Services billed
2,645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan208$295,265
JardianceEmpagliflozin203$276,958
EliquisApixaban180$236,263
CamzyosMavacamten23$172,520
FarxigaDapagliflozin Propanediol35$40,056
XareltoRivaroxaban19$26,327
VascepaIcosapent Ethyl13$14,046
BrilintaTicagrelor13$13,203
Metoprolol Succinate307$4,950
Icosapent Ethyl11$4,213
Atorvastatin Calcium384$3,945
Ezetimibe89$3,198
Rosuvastatin Calcium141$2,897
Bumetanide48$2,095
Eplerenone33$1,926

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$137$295,265208 claims
PfizerEliquis$128$236,263180 claims
E.r. Squibb & Sons, L.L.C.Camzyos$412$172,52023 claims
AstraZenecaFarxiga, Brilinta$130$53,26048 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 111 advanced heart failure and transplant cardiology providers in California.

Other advanced heart failure and transplant cardiology in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →